Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Tekla Life Sciences Investors HQL
$13.86
-$0.05 (-0.36%)
На 18:00, 12 мая 2023
Ключевые показатели
-
Marketcap
356176052.00000000
-
week52high
16.33
-
week52low
13.03
-
Revenue
-103250433
-
P/E TTM
-3
-
Beta
0.83148700
-
EPS
-4.28000000
-
Last Dividend
1.32000000
-
Next Earnings Date
07 мая 2023 г. в 01:26
Описание компании
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Goetz Kathleen | A | 685 | 92 | 23 мар 2022 г. |
| Goetz Kathleen | A | 593 | 593 | 26 янв 2022 г. |
| OMSTEAD DANIEL R | A | 146489 | 6403 | 11 авг 2021 г. |
| OMSTEAD DANIEL R | A | 131836 | 6175 | 26 окт 2020 г. |
| OMSTEAD DANIEL R | A | 125661 | 5950 | 21 окт 2020 г. |
| Bailey Jeffrey Allen | A | 580 | 580 | 22 сент 2020 г. |
| OMSTEAD DANIEL R | A | 114821 | 5950 | 21 мая 2020 г. |
| OMSTEAD DANIEL R | A | 105814 | 8300 | 17 мар 2020 г. |
| Kent Thomas M | A | 1300 | 1300 | 25 янв 2018 г. |
| STEBBINS LUCINDA H | D | 5985 | 1000 | 29 июн 2015 г. |
Новостная лента
HQL: Boom-Bust Returns May Not Be Suitable For High Distribution Yield
Seeking Alpha
08 мар 2023 г. в 03:27
HQL focuses on the life sciences industry with a 74% allocation to biotechnology stocks. It pays a 2% quarterly managed distribution.
Equity CEFs: Top Picks For 2023
Seeking Alpha
09 янв 2023 г. в 12:29
2022 was a year to forget, while most believe 2023 will begin with the same issues that took the equity and bond markets well into bear market territory last year. That is, a hawkish Federal Reserve that doesn't want to let up on strangling inflation into submission while draining market liquidity.
5 Best CEFs To Buy This Month (December 2022)
Seeking Alpha
14 дек 2022 г. в 09:30
For income investors, closed-end funds remain an attractive investment class that covers a variety of asset classes and promises high distributions and reasonable total returns. Closed-end funds are generally characterized by higher volatility and deeper drawdowns than the broad market. For these reasons, they are not suited for everyone.
Equity CEFs: What's Going On With Tekla's HQH And HQL?
Seeking Alpha
08 дек 2022 г. в 10:36
The iShares Biotechnology ETF (IBB) is down -12.9% year-to-date but the Tekla biotech equity CEFs are down even more despite NAVs that are holding up extremely well. The result is that the Tekla biotech CEFs (HQH) and (HQL) keep dropping to lower-and-lower valuations with HQH now at a -11.6% discount and HQL at a -12.0% discount.
Tekla Life Sciences Investors: 10% Yield And Trading 10.5% Below NAV
Seeking Alpha
23 окт 2022 г. в 08:39
Tekla Life Sciences currently has a high 10% yield. The CEF is currently trading 10.5% below NAV, providing a better entry point.